Cerevel Therapeutics Holdings, Inc. Stock
Equities
CERE
US15678U1280
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.1 USD | -0.59% | -0.21% | -0.71% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 7.67B |
---|---|---|---|---|---|
Net income 2024 * | -593M | Net income 2025 * | -559M | EV / Sales 2024 * | - |
Net cash position 2024 * | 619M | Net cash position 2025 * | 690M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-13
x | P/E ratio 2025 * |
-14.6
x | Employees | 355 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.53% |
Latest transcript on Cerevel Therapeutics Holdings, Inc.
1 day | -0.59% | ||
1 week | -0.21% | ||
Current month | -1.43% | ||
1 month | -0.09% | ||
3 months | -1.10% | ||
6 months | +70.86% | ||
Current year | -0.71% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 23-06-11 |
Director of Finance/CFO | 42 | 23-05-14 | |
N. Coles
CHM | Chairman | 63 | 18-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 19-05-31 | |
Ruth McKernan
BRD | Director/Board Member | 66 | 20-12-03 |
Deval Patrick
BRD | Director/Board Member | 67 | 21-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% | ||
0.07% | 1,487 M€ | +9.17% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 42.1 | -0.59% | 1,191,733 |
24-05-16 | 42.35 | +0.09% | 1,083,367 |
24-05-15 | 42.31 | +0.17% | 1,152,247 |
24-05-14 | 42.24 | +0.43% | 726,778 |
24-05-13 | 42.06 | -0.31% | 652,651 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.71% | 7.67B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CERE Stock